Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Gastrointestinal Cancer: A Clinical Investigator Think Tank
Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Gastrointestinal Cancer: A Clinical Investigator Think Tank
Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Gastrointestinal Cancer: A Clinical Investigator Think Tank
Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Gastrointestinal Cancer: A Clinical Investigator Think Tank
Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Gastrointestinal Cancer: A Clinical Investigator Think Tank
Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Gastrointestinal Cancer
In these audio proceedings from a closed Think Tank meeting in Miami, Florida, the invited faculty members discuss and debate current nonprotocol management of various gastrointestinal cancers in addition to relevant papers and presentations emerging over the past year in this area of solid tumor oncology. This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.
RTP TV: Part III — Renal Cell Carcinoma
Select Publications
Select Publications
Aapro M et al. Anthracycline cardiotoxicity in the elderly cancer patient: A SIOG expert position paper. Ann Oncol 2011;22(2):257-67. Abstract
Baselga J et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366(6):520-9. Abstract
Audio Highlights of Challenging Cases in Breast Cancer: Oncologist and Nurse Investigators Consult on Actual Patients from the Practices of the Invited Faculty
In these audio proceedings from a symposium held in conjunction with the Oncology Nursing Society's 2012 Annual Congress, the invited oncology nursing professionals participating as part of our faculty panel present actual patient cases from their practices, setting the stage for faculty discussion of optimal therapeutic and supportive care strategies in breast cancer.
This content is available in a number of formats for listening on the go with a mobile device or in the office or at home on a computer.
Rounds with Investigators 2012 | Breast #10
Rounds with the Investigators 2012 | Breast Cancer
DR NEIL LOVE: Just real quick, actually, Sara: Amazingly we got a communication from a medical oncologist in Nigeria who was asking a question I never heard anybody ask, but I thought it was interesting. At what point may a woman breast-feed from a breast that has had surgery or radiation for breast cancer?
DR SARA HURVITZ: Wow! That’s a very interesting question, and I’ve never heard it. In general, patients of mine who have had breast surgery and radiation and go on to have a pregnancy, they haven’t breast-fed. And I do not know the answer to that question.
Rounds with Investigators 2012 | Breast #9
Rounds with the Investigators 2012 | Breast Cancer
DR NEIL LOVE: Okay. Here’s this one. He’s in Fresno, California, incidentally. I have a 36-year-old woman who presented with inflammatory breast cancer while pregnant. ER-, PR- and HER2-positive with metastatic disease to the spine. Wow! Received TCH, had a complete response, was placed on tamoxifen and trastuzumab. Relapsed 4 months later with brain mets. Wow, this is incredible.
Received whole brain radiation, switched to lapatinib/capecitabine. Local progression in the brain with CR continuing elsewhere. Gets stereotactic radiation. Now she’s progressing in the brain.
Rounds with Investigators 2012 | Breast #8
Rounds with the Investigators 2012 | Breast Cancer
DR NEIL LOVE: So Hal, this one we got, actually, from a colleague of Sara’s at UCLA, Dr Barstis, who apparently is a listener to our audio programs. He’s on the clinical faculty there?
DR SARA HURVITZ: Yes. He actually trained me once upon a time. He’s an excellent clinician. Yes.
Rounds with Investigators 2012 | Breast #7
Rounds with the Investigators 2012 | Breast Cancer
QUESTION: A 77 y/o Afro-American woman with a markedly contracted right breast which on mammography did not demonstrate any finding typical of carcinoma but clinically resembled a carcinoma en cuirasses. Core biopsy showed it to be a Grade I, ER-positive, PR-positive lobular carcinoma.
Rounds with Investigators 2012 | Breast #6
Rounds with the Investigators 2012 | Breast Cancer
DR NEIL LOVE: The second kind of similar case that this physician wanted some input on was a 36-year-old woman with a 2.4-centimeter, ER-positive, HER2-negative tumor. And actually, I guess this physician went ahead and did an Oncotype. The problem is, now the insurance company won’t pay for it, but interestingly, the Oncotype’s low and, as a result, the patient’s not going to get chemo. And the physician pointed out in her note to us how ironic it is that the insurance company won’t pay for something that actually theoretically would save money.
Rounds with Investigators 2012 | Breast #5
Rounds with the Investigators 2012 | Breast Cancer
DR NEIL LOVE: We got a couple of cases from an oncologist in a small town in Illinois, and both of the patients have — I’m not going to identify the insurance company, but apparently not very good insurance that this doc takes and nobody else does. But both patients, the lack of coverage actually affected the management. And they’re both young women that this physician is asking about, Sara. The first one’s 38. Again, difficult time, wasn’t able to get worked up because of the lack of insurance coverage.